It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2019

Evotec and GARDP announce new partnership to discover novel antibiotics
Nerina Coppini, 19 March 2019

Collaboration explores opportunities to set up antibiotic discovery and development platform and establish a joint pipeline of novel antibiotic assets Discovery efforts will focus on World Health Organisation (“WHO”) priority pathogens

Evotec and Galapagos enter into collaboration in the field of Fibrosis
Nerina Coppini, 7 February 2019

Collaboration comprises licence agreement for a programme developed by Evotec as well as its drug discovery capabilities Evotec receives undisclosed upfront payment, adn is eligible for potential milestones as well as royalty payments

2018

Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions
Nerina Coppini, 4 December 2018

Identify new leads for innovative targets in the dermatology field The alliance will use Evotec's world leading drug discovery platform

Evotec and CENTOGENE sign global strategic partnership on drug discovery projects in rare genetic diseases
Nerina Coppini, 27 August 2018

Joint drug discovery projects combine CENTOGENE’s patient access and biomarker expertise with Evotec's leading IPSC platform  

Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity
Nerina Coppini, 22 August 2018

The alliance builds upon Evotec's leading drug discovery and development capabilities in diabetes and related co-morbidities Novo Nordisk accesses Evotec's integrated discovery and development platform to progress new molecules from concept to IND including Evotec's INDiGO platform

2017

Evotec’s Academic Bridge LAB282 with Oxford University Celebrating One Year of Impact
Nerina Coppini, 11 December 2017

THE £ 13 M DRUG DISCOVERY PARTNERSHIP BETWEEN OXFORD UNIVERSITY, OXFORD SCIENCES INNOVATION AND EVOTEC SUPPORTED 12 NEW PROJECTS IN FIRST YEAR OF OPERATION Hamburg, Germany, 11 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that LAB282, the £ 13 m drug discovery partnership between Oxford...

Evotec Receives Clinical Milestone as Part of its Discovery Alliance with Boehringer Ingelheim
Nerina Coppini, 1 December 2017

ACHIEVEMENT MARKS 24TH MILESTONE UNDER ALLIANCE TO DATE Hamburg, Germany, 01 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues of € 2.00 m to Evotec. The milestone was for...

Evotec AG announces first nine-month 2017 results and corporate update
Laura Catalina, 8 November 2017

Strong operational and financial performance Expansion of leading external innovation platform through acquisition of aptuit Important milestone achievements and new ways of accelerating innovation Hamburg, Germany, 08 November 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today reported financial results and...

Evotec joins forces with Academic Leaders to accelerate Drug Discovery in kidney diseases and build “Neplex”
Laura Catalina, 7 November 2017

Collaboration aimed at developing novel “Nephron-on-a Chip” device to test drug candidates in human kidney: NEPLEX (“Nephron-on-a-Chip with Cellular and Extracellular Matrix Complexity”) Major step forward to the next generation Kidney Platform Hamburg, Germany, 06 November 2017:Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN:...

New Research by Cyprotex on Transporter DDI Published in Pharmacology Research & Perspectives
Laura Catalina, 31 October 2017

New research by Cyprotex in the field of metformin drug-drug interactions has been published in Pharmacology Research & Perspectives. The publication assists in further understanding the mechanism behind clinically observed DDIs with the common co-medication, metformin. Read our blog and download the publication. Cyprotex offers a full range of ...

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard